Raj K. Puri, M.D., Ph.D., serves as the Chief Regulatory Officer at Iovance Biotherapeutics Inc., a pioneering biotechnology company focused on developing novel cancer immunotherapies. Dr. Puri brings a wealth of experience and expertise to his role, having dedicated his career to advancing medical research and regulatory affairs in the biopharmaceutical industry. He holds both a medical degree and a doctorate in pharmacology, which have equipped him with a deep understanding of the scientific and clinical aspects of drug development. Prior to joining Iovance Biotherapeutics, Dr. Puri held significant positions at various esteemed organizations, including the U.S. Food and Drug Administration (FDA), where he served as the Director of the Division of Cellular and Gene Therapies. His tenure at the FDA was marked by his instrumental role in the approval of several groundbreaking therapies, showcasing his ability to navigate the complex regulatory landscape effectively. Dr. Puri's academic achievements are equally impressive; he has authored numerous peer-reviewed publications and has been a key contributor to the scientific community's understanding of cellular and gene therapies. As Chief Regulatory Officer at Iovance Biotherapeutics, Dr. Puri is responsible for overseeing the company's regulatory strategy and interactions with global health authorities. His leadership is pivotal in ensuring that Iovance's innovative tumor-infiltrating lymphocyte (TIL) therapies meet the stringent requirements for clinical trials and eventual market approval. Under his guidance, Iovance continues to advance its mission of transforming the treatment landscape for patients with metastatic melanoma and other solid tumor cancers, leveraging Dr. Puri's extensive regulatory experience and scientific acumen to bring these life-saving therapies to market.